Hormos Medical Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: Turku Finland (1997)
Status: Acquired by Quatrx Pharmaceuticals Co (2005) → now Shionogi (2017)

Organization Overview

First Clinical Trial
2006
NCT00276094
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (1)

ospemifene (osphena) (4 trials)

Drugs in Phase 2 Trials (1)

fispemifene (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrophy (Phase 3)

Erectile Dysfunction (Phase 2)

Hypogonadism (Phase 2)

Lung Diseases (Phase 2)

Lung Diseases, Obstructive (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 2)

Vaginal Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 2